Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice

Adrian L. Oblak, Zackary A. Cope, Sara K. Quinney, Ravi S. Pandey, Carla Biesdorf, Andi R. Masters, Kristen D. Onos, Leslie Haynes, Kelly J. Keezer, Jill A. Meyer, Jonathan S. Peters, Scott A. Persohn, Amanda A. Bedwell, Kierra Eldridge, Rachael Speedy, Gabriela Little, Sean Paul Williams, Brenda Noarbe, Andre Obenaus, Michael SasnerGareth R. Howell, Gregory W. Carter, Harriet Williams, Bruce T. Lamb, Paul R. Territo, Stacey J. Sukoff Rizzo

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article numbere12317
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume8
Issue number1
DOIs
StatePublished - 2022

ASJC Scopus Subject Areas

  • Clinical Neurology
  • Psychiatry and Mental health

Keywords

  • BACE inhibitor
  • MODEL-AD
  • amyloid
  • mouse model
  • preclinical testing

Cite this